Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|15|2570-2577

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.15, 2015-08, pp. : 2570-2577

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3212-3220

John Wiley & Sons Inc

Access to resources Recommend Favorite

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : E1-E6

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 3, Iss. 3, 2008-09 ,pp. : 217-227

Bentham Science Publishers

Access to resources Recommend Favorite

Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 121-128

John Wiley & Sons Inc

Access to resources Recommend Favorite